Spots Global Cancer Trial Database for Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer
Official Title: Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer
Study ID: NCT03907800
Study Description
Brief Summary: To evaluate the efficacy and safety of nab-paclitaxel combined with carboplatin for Chinese patients with triple-negative and HER2-positive breast cancer in the neoadjuvant setting.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Ruijin Hospital, Shanghai, , China
Contact Details
Name: Li Zhu, Prof.
Affiliation: Ruijin Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
